Evidera to Acquire Medimix, Expanding Solutions for Real-World Research

Enhances Evidera’s ability to leverage data to provide real-world
evidence and insights for clients

WILMINGTON, N.C.–(BUSINESS WIRE)–Evidera,
a business unit of Pharmaceutical Product Development, LLC (PPD)
and a leading provider of evidence-based solutions demonstrating the
real-world effectiveness, safety and value of health care products, has
entered into an agreement to acquire Medimix
International, a global technology company providing real-world
evidence (RWE) insights and information to the pharmaceutical,
diagnostic and medical device industries. The acquisition will enable
Evidera to offer its customers enhanced technology solutions, real-world
data and access to health care providers.

Medimix solutions help clients gain insight into the real-world
performance and outcomes associated with new treatments. Medimix scans,
extracts and synthesizes big data and evidence-based information using a
proprietary cloud-based visualization and analytics interface. To
generate insights, Medimix uses one of the largest panels of health care
providers globally, totaling 2.2 million clinicians, with a focus on
hematology and oncology.

“The addition of Medimix will expand our ability to help our clients
plan for and generate the evidence needed to optimize the market access
and commercial potential of their products,” said Karen Kaucic, M.D.,
president of Evidera. “We look forward to leveraging the capabilities
and resources of Medimix to develop novel approaches to access and
maximize the utility of real-world data.”

Medimix’s primary solution, LiveTracker™, is a cloud-based platform that
provides real-time monitoring of clients’ particular therapeutic markets
and drugs via key performance indicators and real-world data. It is
unique in its ability to provide robust and comparable real-world
evidence in more than 60 countries, including information on market
structure, drug awareness and level of adoption, patient profiles, and
treatment sequencing and outcomes. Evidera will leverage the platform
and the data it generates to power more efficient and effective
real-world research that addresses burden of illness, resource
utilization, safety, patient outcomes and other endpoints.

“For more than 25 years, Medimix has offered specialized global business
insights and marketing services to the pharmaceutical, diagnostic and
medical device industries,” said Henry Gazay, CEO of Medimix. “By
joining forces with Evidera, we will better support our existing clients
with extended resources and geographic footprint. Our ambition is to
bridge the gap between real-world data used for research and commercial
purposes, and to offer a wide range of new solutions to the
pharmaceutical industry.”

Medimix has been recognized by Pharma Tech Outlook as a top 10
pharma analytics solution provider and by CIO Review as one of
the 20 most promising pharma and life sciences tech solution providers.
The company’s diversified blue-chip customer base includes eight of the
top 10 largest pharmaceutical companies in the world.

Representatives of Evidera and Medimix will attend the annual meeting of
the American Society of Clinical Oncology in Chicago from May 31 to June
4 and will be available at the PPD booth (#22107) to provide additional
information on their expanded capabilities in real-world research.

Berkery Noyes acted as exclusive financial advisor to Medimix.

About Evidera

Evidera, a PPD business unit, is a leading provider of evidence-based
solutions to demonstrate the real-world effectiveness, safety and value
of health care products. We help biopharmaceutical, biotechnology and
medical device companies generate the evidence needed to optimize the
market access and commercial potential of their products. For more
information, visit www.evidera.com.

About PPD

PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and lifecycle
management services. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 48 countries and more than 21,000 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a firm commitment to quality to help clients and partners bend the
cost and time curve of drug development and optimize value in delivering
life-changing therapies to improve health. For more information, visit www.ppdi.com.

About Medimix International

Medimix is a global technology company that specializes in providing
business understanding, real-world evidence insights and information
support to the pharmaceutical, diagnostic and medical device industries.
Our solutions leverage big data and evidence-based information, to
advise and support business decisions in forecasting, marketing,
commercial analytics, business intelligence, health economics, medical
affairs, strategy and licensing. For more information, visit www.medimix.net.

Contacts

Media:
Randy Buckwalter
+1 919 456 4425
[email protected]

Investors:
Nate Speicher
+1 910 558 6783
[email protected]